Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy

Jian-Guo Sun,1–3,* Qin Jiang,4,* Xiao-Pei Zhang,4,* Kun Shan,1 Bai-Hui Liu,5 Chen Zhao,1 Biao Yan1,2 1Eye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China; 2NHC Key Laboratory of Myopia, Fudan University, Key Laboratory of Myopia, Chinese...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sun JG, Jiang Q, Zhang XP, Shan K, Liu B, Zhao C, Yan B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	mesoporous silica nanoparticle bevacizumab ocular angiogenesis anti-angiogenic therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4363da9bc52a487fbef58faa958d597e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4363da9bc52a487fbef58faa958d597e
record_format	dspace
spelling	oai:doaj.org-article:4363da9bc52a487fbef58faa958d597e2021-12-02T02:14:05ZMesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy1178-2013https://doaj.org/article/4363da9bc52a487fbef58faa958d597e2019-02-01T00:00:00Zhttps://www.dovepress.com/mesoporous-silica-nanoparticles-as-a-delivery-system-for-improving-ant-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jian-Guo Sun,1–3,* Qin Jiang,4,* Xiao-Pei Zhang,4,* Kun Shan,1 Bai-Hui Liu,5 Chen Zhao,1 Biao Yan1,2 1Eye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China; 2NHC Key Laboratory of Myopia, Fudan University, Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China; 3Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China; 4The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China; 5Department of Pediatric Surgery, Children’s Hospital of Fudan University, Shanghai, China *These authors contributed equally to this work Purpose: Antiangiogenic drugs usually have short-acting efficacy and poor treatment compliance. The purpose of this study was to determine whether mesoporous silica nanoparticles (MSNs) could be utilized as a nanodrug delivery system for improving antiangiogenic therapy. Materials and methods: MSN-encapsulated bevacizumab nanoparticles were prepared by the nanocasting strategy and characterized by Fourier transform infrared, transmission electron microscopy, and Brunauer–Emmett–Teller method. Encapsulation efficiency and drug loading efficiency of MSN-encapsulated bevacizumab nanoparticles were calculated. The pharmacokinetics, cytotoxicity, and tissue toxicity were evaluated in vitro and in vivo. The antiangiogenic effects of MSN-bevacizumab nanoparticles were evaluated in vitro and in vivo. Results: MSN encapsulation could prolong the residency of bevacizumab in vitreous/aqueous humor and maintain the long-lasting drug concentration. MSN-encapsulated bevacizumab nanoparticles did not show any obvious cytotoxicity and tissue toxicity. MSN-encapsulated bevacizumab nanoparticles were more effective than bevacizumab in suppressing vascular endothelial growth factor-induced endothelial cell proliferation, migration, and tube formation in vitro. MSN-encapsulated bevacizumab nanoparticles showed sustained inhibitory effects on corneal neovascularization and retinal neovascularization in vivo. Conclusion: This study provides a novel strategy of encapsulating bevacizumab to protect and deliver it, which could increase the time between administration and formulation shelf-life. MSN-encapsulated bevacizumab is a promising drug delivery alternative of antiangiogenic therapy. Keywords: mesoporous silica nanoparticle, bevacizumab, ocular angiogenesis, antiangiogenic therapySun JGJiang QZhang XPShan KLiu BZhao CYan BDove Medical Pressarticlemesoporous silica nanoparticlebevacizumabocular angiogenesisanti-angiogenic therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 1489-1501 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	mesoporous silica nanoparticle bevacizumab ocular angiogenesis anti-angiogenic therapy Medicine (General) R5-920
spellingShingle	mesoporous silica nanoparticle bevacizumab ocular angiogenesis anti-angiogenic therapy Medicine (General) R5-920 Sun JG Jiang Q Zhang XP Shan K Liu B Zhao C Yan B Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
description	Jian-Guo Sun,1–3,* Qin Jiang,4,* Xiao-Pei Zhang,4,* Kun Shan,1 Bai-Hui Liu,5 Chen Zhao,1 Biao Yan1,2 1Eye Institute, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China; 2NHC Key Laboratory of Myopia, Fudan University, Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China; 3Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China; 4The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China; 5Department of Pediatric Surgery, Children’s Hospital of Fudan University, Shanghai, China *These authors contributed equally to this work Purpose: Antiangiogenic drugs usually have short-acting efficacy and poor treatment compliance. The purpose of this study was to determine whether mesoporous silica nanoparticles (MSNs) could be utilized as a nanodrug delivery system for improving antiangiogenic therapy. Materials and methods: MSN-encapsulated bevacizumab nanoparticles were prepared by the nanocasting strategy and characterized by Fourier transform infrared, transmission electron microscopy, and Brunauer–Emmett–Teller method. Encapsulation efficiency and drug loading efficiency of MSN-encapsulated bevacizumab nanoparticles were calculated. The pharmacokinetics, cytotoxicity, and tissue toxicity were evaluated in vitro and in vivo. The antiangiogenic effects of MSN-bevacizumab nanoparticles were evaluated in vitro and in vivo. Results: MSN encapsulation could prolong the residency of bevacizumab in vitreous/aqueous humor and maintain the long-lasting drug concentration. MSN-encapsulated bevacizumab nanoparticles did not show any obvious cytotoxicity and tissue toxicity. MSN-encapsulated bevacizumab nanoparticles were more effective than bevacizumab in suppressing vascular endothelial growth factor-induced endothelial cell proliferation, migration, and tube formation in vitro. MSN-encapsulated bevacizumab nanoparticles showed sustained inhibitory effects on corneal neovascularization and retinal neovascularization in vivo. Conclusion: This study provides a novel strategy of encapsulating bevacizumab to protect and deliver it, which could increase the time between administration and formulation shelf-life. MSN-encapsulated bevacizumab is a promising drug delivery alternative of antiangiogenic therapy. Keywords: mesoporous silica nanoparticle, bevacizumab, ocular angiogenesis, antiangiogenic therapy
format	article
author	Sun JG Jiang Q Zhang XP Shan K Liu B Zhao C Yan B
author_facet	Sun JG Jiang Q Zhang XP Shan K Liu B Zhao C Yan B
author_sort	Sun JG
title	Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
title_short	Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
title_full	Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
title_fullStr	Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
title_full_unstemmed	Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
title_sort	mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/4363da9bc52a487fbef58faa958d597e
work_keys_str_mv	AT sunjg mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT jiangq mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT zhangxp mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT shank mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT liub mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT zhaoc mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy AT yanb mesoporoussilicananoparticlesasadeliverysystemforimprovingantiangiogenictherapy
_version_	1718402589520822272

Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy

Ejemplares similares